Orthopedic and Trauma Centers in France
Dr. Issam Mardini is a Syrian National. He obtained his Postgraduate qualifications from France, USA and Germany. He has worked in several Orthopedic and Trauma Centers in France, USA, Germany and UAE. His experience in orthopedic and Trauma Surgeries is more than 30 years.
Regenerative cell therapies may present multiple advantages to clinicians and patients who are looking to improve patient outcomes. These advantages could be obtained through multiple therapeutic modules,Â Since I started this type of treatment on 2006 by injecting PRP directly where it was needed then Gradually started to widen the scope of such therapy by injecting bone marrow extract which also gave as good results as the PRP. Gradually in 2014 we started to add to such treatment the purified Fat extract and in my experience add a wider scope for the treating conditions as well as a far better results from the PRP and finally for the last few years also we added the stem cells therapy extracted from the fat tissue which also added a valuable and effective treatment for managing a lot musculoskeletal cases. In addition to the effective treatment and good results actually, there is a significantly reduced risk of rejection or immune response using autologous biologics as compared to alternative treatment options. Also, there is minimal risk of allergic reactions or tissue rejection. The autologous regenerative therapy uses the normal regeneration and repair processes of the human body.
From my long experience I would like to emphasis that Patients or conditions that are most likely to respond to autologous, biologic-based products have not yet been internationally characterized.Â Therefore, clinical success depends on several factors including diagnosis, the severity of condition being treated, patient age and comorbidities.I will go through this talk in presenting a journey explaining my clinical experience, the way I use and manage regenerative therapy and the success that I achieved during this journey.